Abstract: Novel triazole derivatives of the formula (I) in which R1-R6 and Y have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.

Abstract: The present invention relates to a novel class of aryl-fused spirocyclic compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases.

Abstract: Novel compounds of the formula I (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R, Q, W, X and Z have the meanings indicated in Patent Claim 1, are suitable as antidiabetics.

Abstract: The present invention relates to a novel class of disubstituted aniline compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases.

Abstract: An organic semiconducting layer formulation containing an organic binder which has a permittivity, ?, at 1,000 Hz of 3.3 or less and a polyacene compound of Formula A: and processes for the preparation thereof and uses thereof in various electronic devices.

Abstract: A method of preventing or treating diabetic retinopathy is disclosed including administering to a mammal a therapeutically effective amount of an inhibitor of retinal pericyte apoptosis. Also disclosed is a pharmaceutical composition which treats and/or prevents diabetic retinopathy comprising as an active agent a therapeutically effective amount of at least one inhibitor of retinal pericyte apoptosis and a pharmaceutically acceptable carrier.

Abstract: The invention relates to a birefringent layer having negative optical dispersion, a liquid crystal (LC) medium for its preparation, and the use of the birefringent layer and the LC media in optical, electrooptical, electronic, semiconducting or luminescent components or devices.

Abstract: The present invention relates to white-emitting organic electroluminescent devices which have at least one blue-fluorescent emitter layer and at least one phosphorescent emitter layer.

Abstract: This invention relates to coloured polymer particles preferably with surface functionality for charge retention, a process for their preparation, the use of these particles for the preparation of an electrophoretic device, colour electrophoretic displays comprising such particle, and new water-soluble dyes.

Abstract: The present invention is directed to heterocyclic fused cinnoline compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

Abstract: The invention relates to compounds of the formula (I), in which Ar denotes a mono- or bicyclic aromatic homo- or heterocycle having 1 to 4 N, O and/or S atoms and 5 to 10 skeleton atoms, which may be unsubstituted or mono-, di- or trisubstituted by carbonyl oxygen, Hal, A, OH, OA, NH2, NHA, NA2, NO2, CN, OCN, SCN, COOH, COOA, CONH2, CONHA, CONA2, NHCOA, NHCONH2, NHSO2A, CHO, COA, SO2NH2 and/or S(O)9A, A denotes unbranched, branched or cyclic alkyl having 1-14 C atoms, in which one or two CH2 groups may be replaced by O or S atoms and/or by —CH?CH— groups and/or in addition 1-7 H atoms may be replaced by F and/or Cl, Hal: F, Cl, Br or I, D: NH, NH2, NA2, NHA, CH2, CH3, OH, OA, O or S, E: CH2, CH, NH or N, Y: E or a saturated or unsaturated bond, X: CH2, O or NH, Q: Hal, A, OH, OA, NH2, NHA, NA2, NO2, CN, OCN, SCN, COOH, COOA, CONH2, CONHA, CONA2, NHCOA, NHCONH2, NHSO2A, CHO, COA, SO2NH2 or X-M, to the preparation and use thereof for the preparation of a medicament for the treatment of diseases, in particular t

Abstract: The present invention relates to pearlescent pigments based on flake-form substrates which have at least one FeOOH layer and at least one TiO2 layer or at least one TiO2/SiO2/TiO2 layer package, and to the use thereof, inter alia, in paints, coatings, printing inks, powder coatings, plastics and in particular in care and decorative cosmetics.

Abstract: The present invention relates to the compounds of the formulae (1) to (8) and to the use thereof in organic electroluminescent devices, in particular in blue-emitting devices. The compounds of the formulae (1) to (8) are used as host material or dopant in the emitting layer or also in a hole- or electron-transport layer.

Abstract: The present invention is directed to spiropiperidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

Abstract: The present invention relates to a liquid-crystal (LC) display of the PSA (polymer sustained alignment) type, and to novel polymerisable compounds and novel LC media for use in PSA displays.

Abstract: The invention relates to novel mono-, oligo and polymers of thieno[2,3-b]thiophene, to their use as semiconductors or charge transport materials, in optical, electro-optical or electronic devices like LCDs, optical films, FETs or OFETs for TFT-LCDs and IC devices such as RFID tags, electroluminescent devices in flat panel displays or photovoltaic or sensor devices, and further relates to a FET, light emitting device or ID tag comprising the novel polymers.

Abstract: The present invention relates to dielectrically positive, preferably nematic, media comprising one or more polymerisable compounds, to polymer-stabilised media obtained therefrom, to the use thereof in liquid-crystal displays, and to these displays, in particular PSA-IPS, PSA-FFS and PSA-positive VA displays

Abstract: The present invention relates to biaryl piperidine-based renin inhibitor compounds, and their use in treating cardiovascular events and renal insufficiency.

Abstract: The invention relates to oxadiazole compounds of formula I. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.

Abstract: MicroRNAs (miRNAs) are short non-coding RNAs that regulate gene expression and which play important roles in many cell types, including as described herein, the pancreatic ?-cell. Glucagon like peptide-1 (GLP-1), a hormone released from intestinal L-cells following meal intake, exerts pleiotropic effects on ?-cell function including raising intracellular cAMP levels and now represents an important therapy for type 2 diabetes. Expression of miR-132 and miR212 is upregulated by CREB protein in response increased cAMP levels in the cell; therefore, methods for detecting and evaluating ?-cell engagement by GLP-1 receptor agonists by monitoring miR-132 and miR-212 expression in a subject is described. The methods herein are particularly useful in the context of longitudinal clinical trials, such as those designed for testing the durability of any single or combination therapy in type 2 diabetes populations.